

*For Health Professionals Who Care for People with Cancer*

## Inside This Issue:

### Editor's Choice

#### New Programs

**GIAVPEMPG:** First-Line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum

**UGUPAVNABI:** Treatment for Metastatic Castration-Resistant Prostate Cancer using Niraparib-Abiraterone and Prednisone

**ULYOGLOFIT:** Treatment of Lymphoma using Glofitamab

#### Cancer Drug Manual®

**New:** Niraparib-abiraterone, Glofitamab, Dostarlimab

**Revised:** Daunorubicin, Daunorubicin-cytarabine liposome, Doxorubicin, Doxorubicin pegylated liposomal, Epirubicin, Idarubicin, Mitoxantrone, Palbociclib

**Retired:** Palbociclib Capsule Patient handout

**Chemotherapy Preparation and Stability Chart:**

Dexrazoxane, Paclitaxel NAB

**Auxiliary Label List:** Palbociclib capsule

**Revised Dose Conversions for Anthracyclines Exposure**

**Announcements:** NIOSH List of Hazardous Drugs in Healthcare Settings

### Continuing Education

Family Practice Oncology Network

### Benefit Drug List

**New:** GIAVPEMPG, UGUPAVNABI, ULYOGLOFIT

### New Protocols, PPPOs and Patient Handouts

**GI** GIAVPEMPG | **GU** UGUPAVNABI | **LY** ULYOGLOFIT

### REVISED Protocols, PPPOs and Patient Handouts

**BR** BRAVEVEX | **GI** GIAVDURPG | **GU** GUMCSPABI, GUMCSPAPA, UGUMCSPDD, GUMCSPENZ, UGUNMPENZ, UGUPABI, UGUPAPA, UGUPAVOABI, UGUPENZ, UGUPOLAP | **HN** HNOTLEN | **LU** LUAJNIVPP, LUAJNP, LUAJPP, LUAVPEM, LUAVPMTN, LUAVPP, LUAVPIPNI, LUAVPPMB, LUMMPP, LUNETEV | **LY** LYBENDO, LYCHOPO, LYCVPO, ULYPCOR, LYEPOCHR, LYGDPO, LYOBCHLOR, LYVENOB | **SC** SCCRS

### Resources and Contact Information

## Editor's Choice

### New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 March 2025. Full details of all treatment programs are available in the Chemotherapy Protocols section of the BC Cancer website.

#### Gastrointestinal

**First-Line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum (GIAVPEMPG)** – The BC Cancer Gastrointestinal Tumour Group is introducing pembrolizumab in combination with gemcitabine and platinum as an alternative treatment for patients with metastatic or unresectable biliary tract cancer. Patients are eligible if they have not received prior systemic treatment in the advanced setting or experience a recurrence a minimum of 6 months after prior adjuvant treatment. Currently the standard therapy for these patients is durvalumab in combination with gemcitabine and platinum.

## Editor's Choice

The new treatment is supported by evidence from a phase III trial, KEYNOTE-966, showing improved overall survival compared to gemcitabine-based chemotherapy alone.<sup>1,2</sup> The combination regimen is associated with manageable toxicities consistent with the known safety profile of pembrolizumab, gemcitabine and platinum.<sup>1</sup>

### Genitourinary

**Treatment of Metastatic Castration-Resistant Prostate Cancer using Niraparib-Abiraterone and Prednisone (UGUPAVNABI)** – The BC Cancer Genitourinary Tumour Group is introducing the combination product niraparib-abiraterone (AKEEGA) and prednisone for patients with metastatic castration-resistant prostate cancer (mCRPC) that have a deleterious germline and/or somatic *BRCA1* or *BRCA2* gene alteration. Patients are eligible if they have confirmed *BRCA 1/2* mutations and have not been treated with an androgen receptor pathway inhibitor for earlier stages of prostate cancer or a PARP inhibitor for mCRPC. BC Cancer Compassionate Access Program (CAP) approval is required prior to treatment.

This treatment is supported by evidence from a phase III trial, MAGNITUDE, showing improved radiographic progression free survival associated with the combination product with prednisone compared to abiraterone only with prednisone.<sup>3,4</sup> This new treatment is associated with manageable toxicities consistent with the known safety profile of niraparib, abiraterone and prednisone.

### Lymphoma

**Treatment of Lymphoma using Glofitamab (ULYOGLOFIT)** – The BC Cancer Lymphoma Tumour Group is introducing glofitamab for the treatment of relapsed or refractory B-cell lymphoma. Patients are eligible if they have received two or more lines of systemic therapy, including CAR T-cell therapy, unless unable to receive. BC Cancer Compassionate Access Program (CAP) approval is required prior to treatment.

Glofitamab is a bispecific T-cell engager that simultaneously binds to CD20 on B-cells and CD3 receptors on T-cells. Evidence from an ongoing phase I/II trial indicates that treatment with glofitamab may result in significant improvements in overall survival and progression free survival.<sup>5,6</sup> Glofitamab was also associated with a clinically meaningful complete response rate and durable response.<sup>6</sup> Glofitamab is associated with cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), tumour flare, neutropenia, thrombocytopenia, lymphopenia and leukopenia. Patients are routinely pre-treated with obinutuzumab to mitigate CRS.

#### References:

1. Kelley RK, Ueno M, Yoo C, et al; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomized, double-blind, placebo-controlled phase 3 trial. *Lancet* 2023 Jun 3;401(10391):1853-1865.
2. Pembrolizumab (Keytruda) CADTH Reimbursement Recommendation. *Canadian Journal of Health Technologies* Jul 2024; 4(7): 1-26.
3. Chi KN, Rathkopf D, Smith MR, et al; MAGNITUDE Principal Investigators. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. *J Clin Oncol*. 2023 Jun 20;41(18):3339-3351.
4. Niraparib and Abiraterone Acetate (Akeega) CADTH Reimbursement Recommendation. *Canadian Journal of Health Technologies*. Feb 2024; 4(2):1-24.
5. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large b-cell lymphoma. *N Engl J Med*. 2022 Dec 15;387(24):2220-2231.
6. Glofitamab (Columvi) CADTH [Canada's Drug Agency (CDA-AMC)] Reimbursement Recommendation. *Canadian Journal of Health Technologies* Feb 2024; 4(2): 1-27.

All documents are available in the [Cancer Drug Manual<sup>®</sup>](#) on the BC Cancer website.

### New Documents

The **Niraparib-Abiraterone Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Krista Noonan (medical oncologist, BC Cancer Genitourinary Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). Niraparib-abiraterone is a combination drug product containing niraparib (PARP inhibitor) and abiraterone (CYP17 enzyme inhibitor). The usual dose for the treatment of advanced prostate cancer is two tablets taken once daily on a continuous basis, providing niraparib 200 mg and abiraterone 1000 mg per day.

Highlights from these documents include:

- treatment-associated hypertension, hypokalemia, and fluid retention may worsen pre-existing cardiovascular disease; blood pressure should be adequately controlled prior to starting treatment
- hematologic toxicity mostly occurs during the first two months of treatment
- severe hepatotoxicity with marked increased in liver enzymes can occur with niraparib-abiraterone

**Niraparib-abiraterone** has been added to the **Auxiliary Label List** and evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

The **Glofitamab Monograph** and **Patient Handout** have been developed. Dr. Laurie Sehn (medical oncologist, BC Cancer Lymphoma Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy) provided expert review. Glofitamab is a bispecific T-cell engager that simultaneously binds to CD20 on B cells and CD3 receptors on T-cells. Glofitamab is used in the treatment of B-cell lymphoma. Cycle 1 includes pre-treatment with obinutuzumab followed by a step-up dosing regimen given IV weekly for 2 weeks. For cycle 2 to 12, the usual dosing is 30 mg IV given on day 1 of a 21-day cycle.

Highlights from these documents include:

- ***cytokine release syndrome (CRS)*** commonly occurs; to mitigate the risk of CRS, glofitamab is initiated in a step-up dosing regimen
- ***immune effector cell-associated neurotoxicity syndrome (ICANS)*** has been reported; most events occur during cycle 1 and 2
- patients with bulky tumours near airways or a vital organ are at increased risk of ***tumour flare***

**Glofitamab** has been added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

The **Dostarlimab Monograph** has been expanded and a **Patient Handout** has been developed. Expert review was provided by Megan Darbyshire and Robert Tillmanns (tumour group pharmacists, BC Cancer Provincial Pharmacy). All monograph sections have been reviewed and updated.

The following sections have been added or expanded:

*Pharmacokinetics*      *Special Precautions*      *Dosage Guidelines*      *Interactions*      *Side Effects*

**Dostarlimab** is an active immune-checkpoint inhibitor targeting the PD-1 receptor on T cells. Dostarlimab is used in the treatment of endometrial cancer. The usual dose is 500 mg IV on day 1 of a 21-day cycle and follows BC Cancer Protocols UGOEAVDCAT and UGOEAVDPNT.

Highlights from these documents include:

- refer to BC Cancer protocol SCIMMUNE to manage immune-mediated adverse reactions
- infusion-related reactions are rare, but can be severe

**Dostarlimab** has been added to the **Chemotherapy Preparation and Stability Chart**, and **Extravasation Hazard Table**.

### Revised Documents

#### **Daunorubicin Monograph**

*Cautions:* updated *Carcinogenicity* and *Pregnancy* sections

*Side Effects paragraphs (cardiac toxicity):* deleted “Dose Conversion Table for Anthracyclines” and replaced it with link to updated table in the CDM Appendix

*Supply and Storage:* updated to include current Canadian brands

*Parenteral Administration table:* updated ‘direct intravenous’ with link to Systemic Therapy Policy III-20 as per current template

*Dosage Guidelines (Suggested maximum lifetime dose):* updated per current product information

#### **Daunorubicin-cytarabine liposome Monograph**

*Side Effects paragraphs (cardiotoxicity):* included link to “Dose Conversion Table for Anthracyclines” in the CDM Appendix

#### **Dexrazoxane Chemotherapy Preparation and Stability Chart**

*Product column:* updated range of volumes for bag size selection

#### **Doxorubicin Monograph**

*Cautions:* updated *Carcinogenicity*, *Fertility*, and *Pregnancy* sections

*Side Effects paragraphs (cardiac toxicity):* deleted “Dose Conversion Table for Anthracyclines” and replaced it with link to updated table in the CDM Appendix

#### **Doxorubicin pegylated liposomal Monograph**

*Side Effects paragraphs (cardiotoxicity):* included link to “Dose Conversion Table for Anthracyclines” in the CDM Appendix

*Supply and Storage:* updated to include current Canadian brands

*Parenteral Administration table:* updated ‘direct intravenous’ with link to Systemic Therapy Policy III-20 as per current template

*Dosage Guidelines (Suggested maximum lifetime dose):* updated per current product information

*Dosage Guidelines (Concurrent radiation):* updated per current protocol

#### **Epirubicin Monograph**

*Cautions:* updated *Carcinogenicity*, *Fertility*, and *Pregnancy* sections

*Side Effects paragraphs (cardiac toxicity):* deleted “Dose Conversion Table for Anthracyclines” and replaced it with link to updated table in the CDM Appendix

*Supply and Storage:* updated to include current Canadian brands

*Parenteral Administration table:* updated ‘direct intravenous’ with link to Systemic Therapy Policy III-20 as per current template

*Dosage Guidelines (Suggested maximum lifetime dose):* updated per current product information

### **Idarubicin Monograph**

*Cautions:* updated *Mutagenicity, Fertility, Pregnancy, and Breastfeeding* sections

*Side Effects paragraphs (cardiac toxicity):* deleted “Dose Conversion Table for Anthracyclines” and replaced it with link to updated table in the CDM Appendix

*Supply and Storage:* updated to include current Canadian brands

*Parenteral Administration table:* updated ‘direct intravenous’ with link to Systemic Therapy Policy III-20 as per current template

### **Mitoxantrone Monograph**

*Cautions:* updated *Mutagenicity, Fertility, Pregnancy, and Breastfeeding* sections

*Side Effects table (extravasation):* deleted details from table and added cross reference to Side Effects paragraph instead

*Side Effects paragraphs (cardiac toxicity):* deleted “Dose Conversion Table for Anthracyclines” and replaced it with link to updated table in the CDM Appendix

*Side Effects paragraphs (local tissue damage):* added new paragraph to include details about extravasation (to support assigned extravasation hazard)

*Supply and Storage:* updated to include current Canadian brands

### **Paclitaxel NAB Chemotherapy Preparation and Stability Chart**

*Drug & Strength column:* updated ABRAXANE<sup>®</sup> brand to include both Celgene and BMS as manufacturer (NOTE: packaging may indicate manufacturer as Celgene [old supply] or BMS [new supply]; products have the same DIN# and are otherwise the same)

### **Palbociclib Monograph**

*Supply and Storage:* deleted the capsule formulation as no longer available in Canada

## Retired Documents

The **Palbociclib capsule Patient Handout** has been retired.

## Revised Dose Conversions for Anthracyclines Exposure

The dose conversions for cumulative exposure of anthracyclines and mitoxantrone have been revised based on the latest updates of the Children’s Oncology Group (COG) Long-Term Follow-Up Guidelines,<sup>1</sup> which have adopted new data of long-term cardiotoxicity of anthracyclines and mitoxantrone.<sup>2</sup> The revised dose conversion is now available as a standalone table on the BC Cancer Drug Manual<sup>©</sup> Appendix webpage, as well as linked to the relevant individual monographs. The table provides fixed conversion factors rather than the previous ranges and includes information on liposomal anthracyclines products.

## Cancer Drug Manual<sup>©</sup>

### References

1. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 6.0. Children's Oncology Group, October 2023. Available at: [www.survivorshipguidelines.org](http://www.survivorshipguidelines.org). Accessed 21 March 2024.
2. Feijen EAM, Leisenring WM, Stratton KL, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019;5(6):864-71.

## CDM Announcements

The NIOSH List of Hazardous Drugs in Healthcare Settings was updated December 2024. The **BC Provincial Hazardous Drug List** will be updated with relevant changes from the updated NIOSH List on March 1, 2025. The Hazardous Drug List can be accessed from the Cancer Drug Manual homepage - see [Hazardous Drug List](#).

## Continuing Education

### Family Practice Oncology Network

The Family Practice Oncology Network (FPON) is pleased to announce a webinar session on Post-Breast Cancer Treatment Follow-up with Dr. Karen Gelmon, on Thursday 20 March 2025, from 8 to 9 am, as part of the Complimentary Accredited Webinar Series.

By the end of the session, participants will be able to:

- Cite post-breast cancer treatment surveillance
- Describe short-term side effect monitoring recommendations of patients on hormone therapy
- Discuss the late effects of breast cancer treatments

For more information and link to registration, visit:

<https://ubccpd.ca/learn/learning-activities/course?eventtemplate=904-fpon-webinar-postbreast-cancer-treatment-followup-care>

## Benefit Drug List

### New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 March 2025:

Protocol Title	Protocol Code	Benefit Status
First-line Palliative Treatment of Advanced Biliary Tract Cancer using <b>Pembrolizumab, Gemcitabine</b> and <b>Platinum</b>	<b>GIAVPEMPG</b>	Class I
Treatment for Metastatic Castration-Resistant Prostate Cancer using <b>Niraparib-Abiraterone</b> and <b>Prednisone</b>	<b>UGUPAVNABI</b>	Restricted
Treatment of Lymphoma using <b>Glofitamab</b>	<b>ULYOGLOFIT</b>	Restricted

### Highlights of New & Revised Protocols, PPPOs and Patient Handouts

**BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts** are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

#### NEW Protocols, PPPOs and Patient Handouts (*new documents checked* )

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GIAVPEMPG</b>	First-line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<b>UGUPAVNABI</b>	Treatment for Metastatic Castration-Resistant Prostate Cancer using Niraparib-abiraterone and prednisone	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<b>ULYOGLOFIT</b>	Treatment of Lymphoma using Glofitamab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

#### REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>BR   Breast</b>				
<b>BRAVEVEX</b>	Therapy for Advanced Breast Cancer Using Everolimus and Exemestane	<i>Tests, dose modifications and precautions updated, dosing clarified</i>	<i>Tests updated</i>	--
<b>GI   Gastrointestinal</b>				
<b>GIAVDURPG</b>	First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum	<i>Eligibility updated, exclusion added</i>	--	--

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GU   Genitourinary</b>				
<b>GUMCSPABI</b>	Therapy for Metastatic Castration Sensitive Prostate Cancer using Abiraterone and Prednisone	<i>Eligibility updated</i>	--	--
<b>GUMCSPAPA</b>	Treatment of Metastatic Castration Sensitive Prostate Cancer using Apalutamide	<i>Eligibility updated</i>	--	--
<b>UGMCSPDD</b>	Treatment of Metastatic Castration Sensitive Prostate Cancer using Darolutamide and Docetaxel	<i>Eligibility updated</i>	--	--
<b>GUMCSPENZ</b>	Treatment for Metastatic Castration Sensitive Prostate Cancer using Enzalutamide	<i>Eligibility updated</i>	--	--
<b>UGUNMPDAR</b>	Treatment of Non- Metastatic Castration Resistant Prostate Cancer Using Darolutamide	<i>Eligibility updated</i>	--	--
<b>UGUNMPENZ</b>	Therapy for Non-Metastatic Castration Resistant Prostate Cancer Using Enzalutamide	<i>Eligibility updated</i>	--	--
<b>UGUPABI</b>	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and Prednisone	<i>Eligibility updated</i>	--	--
<b>UGUPAPA</b>	Treatment of Non- Metastatic Castration Resistant Prostate Cancer Using Apalutamide	<i>Eligibility updated</i>	--	--
<b>UGUPAVOABI</b>	Treatment for Metastatic Castration-Resistant Prostate Cancer using Olaparib with Abiraterone and Prednisone	<i>Eligibility and exclusions updated</i>	--	--
<b>UGUPENZ</b>	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Enzalutamide	<i>Eligibility updated</i>	--	--
<b>UGUPOLAP</b>	Treatment of Metastatic Castration-Resistant Prostate Cancer using Olaparib	<i>Exclusions added</i>	--	--
<b>HN   Head and Neck</b>				
<b>HNOTLEN</b>	Therapy for Locally Recurrent or Metastatic, RAI-refractory Differentiated Thyroid Cancer Using Lenvatinib	<i>Emetogenic risk category updated</i>	--	--
<b>LU   Lung</b>				
<b>LUAJNIVPP</b>	Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum	<i>Tests and dose modifications updated, duplicate hyperlinks removed</i>	<i>Tests updated</i>	--
<b>LUAJNP</b>	Adjuvant Cisplatin and Vinorelbine Following Resection of Non-Small Cell Lung Cancer	<i>Eligibility, treatment dose modifications and precautions updated, exclusions removed</i>	<i>Treatment and tests updated</i>	--



## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>LUAJPP</b>	Adjuvant Cisplatin and Pemetrexed Following Resection of Non-Small Cell Lung Cancer	<i>Tests and dose modifications updated</i>	<i>Tests updated</i>	--
<b>LUAVPEM</b>	Second-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer With Pemetrexed	<i>Tests and dose modifications updated, minor formatting</i>	<i>Tests updated</i>	--
<b>LUAVPMTN</b>	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer With Pemetrexed	<i>Tests and dose modifications updated, minor formatting</i>	<i>Tests updated</i>	--
<b>LUAVPP</b>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Pemetrexed	<i>Tests and dose modifications updated, minor formatting</i>	<i>Tests updated</i>	--
<b>LUAVPPIPNI</b>	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	<i>Tests and dose modifications updated</i>	<i>Tests updated (Cycle 1-2 PPPO)</i>	--
<b>LUAVPPMB</b>	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed and Pembrolizumab	<i>Tests and dose modifications updated, duplicate hyperlinks removed</i>	<i>Tests updated</i>	--
<b>LUMMPP</b>	Treatment of Malignant Mesothelioma with Platinum and Pemetrexed	<i>Tests and dose modifications updated, minor formatting</i>	<i>Tests updated</i>	--
<b>LUNETEV</b>	Treatment of Advanced Neuroendocrine Tumours of Lung Origin (Non-Functional) Using Everolimus	<i>Eligibility, notes, exclusion, treatment, dose modifications and precautions updated</i>	<i>Tests updated</i>	--
<b>LY   Lymphoma</b>				
<b>LYBENDO</b>	Treatment of Rituximab-refractory Follicular Lymphoma with Bendamustine in Combination with Obinutuzumab	<i>Treatment sequence changed, Title, tests, premedications, supportive medications, treatment, observation, vitals, and precautions updated, appendix clarified</i>	<i>Premedications, observation, vital sign requirements and tests updated, treatment sequence changed</i>	--
<b>LYCHOPO</b>	Treatment of Rituximab-refractory Follicular Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, and Obinutuzumab	<i>Premedications, observation, vitals, and precautions updated, supportive medications and appendix clarified</i>	<i>Premedications, observation and vital sign requirements updated</i>	--

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>LYCVPO</b>	Treatment of Rituximab-refractory Follicular Lymphoma with Cyclophosphamide, Vincristine, Prednisone and Obinutuzumab	<i>Premedications, observation, vitals and precautions updated, supportive medications and appendix clarified</i>	<i>Premedications, observation, vital sign requirements, and tests updated</i>	--
<b>ULYPCOR</b>	Treatment of Lymphoma using Epcoritamab	<i>Eligibility, tests, and precautions updated</i>	<i>Tests updated</i>	--
<b>LYEPOCHR</b>	Treatment of Lymphoma with Dose Adjusted Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone and Rituximab with Intrathecal Methotrexate	<i>Tests clarified</i>	--	--
<b>LYGDPO</b>	Treatment of Rituximab-refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and Obinutuzumab	<i>Premedications, observation, vitals and precautions updated, supportive medications and appendix clarified</i>	<i>Premedications, vital sign requirements, and tests updated</i>	--
<b>LYOBCHLOR</b>	Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with Obinutuzumab and Chlorambucil	<i>Tests, premedications, observation, vitals, and precautions updated. Appendix clarified</i>	<i>Treatment clarified, premedications, observation, vitals, and tests updated</i>	--
<b>LYVENOB</b>	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Obinutuzumab	<i>Premedications and administration clarified, tests, vitals, observation, precautions, and appendix updated</i>	<i>Premedications and rate clarified, observation, vital sign requirements, and tests updated</i>	--
<b>SC   Supportive Care</b>				
<b>SCCRS</b>	Cytokine Release Syndrome Management	<i>Grade 1 and 2 sections updated</i>	<i>Grade 1 and 2 sections updated</i>	--

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 <a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCCancerPPNAdmin@phsa.ca">BCCancerPPNAdmin@phsa.ca</a>
Provincial Systemic Therapy Network	604-877-6000 x 672247	<a href="mailto:ProvincialSystemicOffice@bccancer.bc.ca">ProvincialSystemicOffice@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)  
 Jelena Mucovic, BScPharm (Assistant Editor)  
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC  
 Alison Pow, BScPharm  
 Yuna Jang, RN